Latest news with #sensitivity
Yahoo
a day ago
- Business
- Yahoo
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
DOYLESTOWN, Pa., June 27, 2025--(BUSINESS WIRE)--Metabolics Pharma ("Metabolics"), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that its drug candidate, ENT-03, showed significant benefit in metabolic dysfunction in addition to sustaining weight loss, improvement in blood glucose, and insulin sensitivity in comparison to semaglutide in an animal model for obesity. "Metabolics Pharma spun off from its parent company, Enterin, in late 2024 so that the company could focus its efforts on and enhance the value of its lead asset, ENT-03, for the treatment of obesity and certain comorbidities," said Richard Larson, M.D., Ph.D., Chief Executive Officer, Chief Medical Officer and Board Chairman of Metabolics Pharma. "These preclinical data highlight both the promise and potential value of ENT-03 in the treatment of metabolic disease. The research shows that ENT-03 clearly improves insulin sensitivity and sustained weight reduction that persists following cessation of treatment. This research is the foundation for our Phase 1 clinical trials in healthy obese and diabetic obese subjects." ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism. In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function. This study compared ENT-03 to semaglutide, a combination of the two compounds, and vehicle in Diet Induced Obesity (DIO) mice. While the vehicle-treated mice gained weight through the duration of the study, mice treated with ENT-03, Semaglutide, or a combination of the two drugs all lost weight and reduced insulin and glucose levels. ENT-03 showed a greater reduction in weight than Semaglutide over the 10-week treatment period. Additive weigh loss was seen when the drugs were used in combination. After cessation of therapy, weight loss and reduction in glucose and insulin were sustained for an additional two months in the ENT-03 treated mice but not Semaglutide treated mice. In addition, ENT-03 showed substantially greater preservation of lean mass in comparison to other treatment groups. "GLP-1 agonists have revolutionized the treatment of obesity and type 2 diabetes," said Richard Larson, MD, PhD. "However, their impressive efficacy comes at the price of tolerability challenges, the loss of lean body mass, and the need to remain on treatment to sustain weight loss. ENT-03 represents a novel drug candidate that could be an alternative treatment to GLP-1 agonists or used in combination with them. We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss." Metabolics Pharma has completed a Phase 1a, first in human, randomized, double-blind, single ascending dose study of ENT-03. Results of the Phase 1a trial were presented at the American Diabetes Association 85th Scientific Sessions on June 22, 2025. A Phase 1b clinical trial is planned to initiate in the second half of 2025. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity and type 2 diabetes. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit View source version on Contacts Richard Larson, M.D., Executive Officer, Chief Medical Officer, and Chairman of the Board John DessoukiChief Financial Sign in to access your portfolio
Business Wire
a day ago
- Business
- Business Wire
Metabolics Pharma Announces ENT-03 Generates Sustained Weight Loss and Liver Pathology Improvements in an Animal Model for Obesity
DOYLESTOWN, Pa.--(BUSINESS WIRE)--Metabolics Pharma ('Metabolics'), a privately held, Doylestown-based, clinical-stage biopharmaceutical company pioneering novel treatments for metabolic diseases, today announced that its drug candidate, ENT-03, showed significant benefit in metabolic dysfunction in addition to sustaining weight loss, improvement in blood glucose, and insulin sensitivity in comparison to semaglutide in an animal model for obesity. 'Metabolics Pharma spun off from its parent company, Enterin, in late 2024 so that the company could focus its efforts on and enhance the value of its lead asset, ENT-03, for the treatment of obesity and certain comorbidities,' said Richard Larson, M.D., Ph.D., Chief Executive Officer, Chief Medical Officer and Board Chairman of Metabolics Pharma. 'These preclinical data highlight both the promise and potential value of ENT-03 in the treatment of metabolic disease. The research shows that ENT-03 clearly improves insulin sensitivity and sustained weight reduction that persists following cessation of treatment. This research is the foundation for our Phase 1 clinical trials in healthy obese and diabetic obese subjects.' ENT-03 is a novel, centrally acting aminosterol with Protein Tyrosine Phosphatase 1B (PTP1B) inhibitory activity, which normalizes glucose and causes weight loss by acting on brain circuits that regulate energy and metabolism. In obese, diabetic mice, ENT-03 rapidly lowers blood glucose, reduces food intake and adiposity, eliminates liver fat, and improves liver function. This study compared ENT-03 to semaglutide, a combination of the two compounds, and vehicle in Diet Induced Obesity (DIO) mice. While the vehicle-treated mice gained weight through the duration of the study, mice treated with ENT-03, Semaglutide, or a combination of the two drugs all lost weight and reduced insulin and glucose levels. ENT-03 showed a greater reduction in weight than Semaglutide over the 10-week treatment period. Additive weigh loss was seen when the drugs were used in combination. After cessation of therapy, weight loss and reduction in glucose and insulin were sustained for an additional two months in the ENT-03 treated mice but not Semaglutide treated mice. In addition, ENT-03 showed substantially greater preservation of lean mass in comparison to other treatment groups. 'GLP-1 agonists have revolutionized the treatment of obesity and type 2 diabetes,' said Richard Larson, MD, PhD. 'However, their impressive efficacy comes at the price of tolerability challenges, the loss of lean body mass, and the need to remain on treatment to sustain weight loss. ENT-03 represents a novel drug candidate that could be an alternative treatment to GLP-1 agonists or used in combination with them. We believe that ENT-03 could have a substantial impact on the obesity drug market since it has potential benefits beyond weight loss.' Metabolics Pharma has completed a Phase 1a, first in human, randomized, double-blind, single ascending dose study of ENT-03. Results of the Phase 1a trial were presented at the American Diabetes Association 85 th Scientific Sessions on June 22, 2025. A Phase 1b clinical trial is planned to initiate in the second half of 2025. About Metabolics Pharma Metabolics Pharma develops novel therapies for the treatment of metabolic diseases including obesity and type 2 diabetes. The Company's lead compound, ENT-03, in development for the treatment of type 2 diabetes and obesity, increases insulin sensitivity by acting at the level of the brain. ENT-03 has completed a Phase 1a clinical trial and will begin a Phase 1b clinical trial in the second half of 2025. For more information, please visit
New York Post
3 days ago
- Science
- New York Post
Astronomers make groundbreaking discovery about largest comet ever observed flying through deep space
A groundbreaking discovery was recently made about the largest comet ever observed hurtling toward the sun from the Oort Cloud in the outer reaches of our solar system. Astronomers recently got a close-up look at the comet, known as C/2014 UN271, flying through deep space with the powerful Atacama Large Millimeter/submillimeter Array (ALMA) radio telescope in Chile. The icy giant is 85 miles across and is more than 10 times the size of any known comet, according to the National Radio Astronomy Observatory (NRAO). The NRAO reported that astronomers found that new observations from the comet showed jets of carbon monoxide gas erupting out from the comet's solid icy core. Using the ALMA, the researchers found the comet in deep space near Neptune or about 17 times the distance between the Sun and Earth, according to a release from NRAO. Using the ALMA telescope's high sensitivity and resolution, the researchers were able to focus on the carbon monoxide and heat being emitted from the comet. Nathan Roth of American University and NASA Goddard Space Flight Center, the lead author of the study, which was published in the Astrophysical Journal Letters, discussed how this gives researchers insight into the workings of this frozen rock hurtling through space. 4 Astronomers discovered jets of carbon monoxide gas erupting out from the comet's solid icy core. NRAO/Melissa Weiss 4 The comet was spotted in deep space near Neptune. NASA Goddard 'These measurements give us a look at how this enormous, icy world works,' Roth said. 'We're seeing explosive outgassing patterns that raise new questions about how this comet will evolve as it continues its journey toward the inner solar system.' Using previous ALMA observations and these newest findings, researchers were able to measure the comet. They measured the thermal signal to find the comet's size and amount of dust surrounding its core. 4 Scientists hope the new data will give them a better understanding of the makeup of the solar system. AP 4 Researchers used the ALMA telescope to track the carbon monoxide and heat being emitted from the comet. Diogo Josí© – Researchers believe that as C/2014 UN271 gets closer to the sun, they will see more frozen gas begin to vaporize off the titan of a comet. This could possibly give researchers more information about the primitive makeup of this icy giant. The researchers also hope that this will give a better understanding of the makeup of the solar system.
India.com
5 days ago
- Entertainment
- India.com
Days after the Ahmedabad plane Crash, Air India staff seen dancing, partying in office; Netizens slam airline - 'Koi marta hai toh...'
Days after the Ahmedabad plane Crash, Air India staff seen dancing, partying in office; Netizens slam airline - 'Koi marta hai toh...' Just when we were trying to recover from the deadliest air disaster of the recent past, a video of Air India senior officials is doing the rounds on the internet, making people question humanity and sensitivity. On June 12, 2025, a horrific incident of Air India Flight A171 took place, which not only killed nearly 247 people on board with just one survivor but turned out to be India's deadliest aviation accident in over a decade. The Dreamliner Boeing 787-8 crashed barely 38 seconds after its takeoff, allegedly because of both engines' failure. Besides the passengers, it also took the lives of several people on the ground as the plane bumped into the building near BJ Medical College. While the family of the victims and the nation are still mourning the lost lives, footage of AISATS (Air India SATS) went viral, where their executives, including the COO Abraham Zakaria and Air India's CFO, are seen dancing and enjoying the Bollywood songs Ladki Beautiful Kar Gayi Chull. The celebrations were happening in their Gurgaon, Haryana office. View this post on Instagram A post shared by mid-day (@middayindia) As soon as the video went viral on social media, netizens were quick to comment on the poor timing, lack of basic humanity, and insensitivity of the Air India officials. While one user commented, 'Humanity loses, unbelievable,' another said, 'Uska ghar ka koi nahi mara… marta to aisa nahi hota.' ('No one from their family died—if they had, this wouldn't be happening.') Following this insensitive celebration of Air India officials, AISATS has now issued a public apology. In a statement to IANS, they shared – 'AISATS is aware of a video being circulated on social media that, unfortunately, is completely out of context. Notwithstanding, we sincerely regret any emotional discomfort this may have caused.' However, despite the apology, the damage has already been done, and people's rage and anger remain.
Yahoo
7 days ago
- Entertainment
- Yahoo
Alanis Morissette Says Work, Love, Sex and Shopping are Her ‘Whac-a-Mole' Addictions: ‘There's No Worth in Just Being'
Alanis Morissette is known for her honesty. In an expansive interview published on The Guardian on Saturday, the singer admitted to several addictions — or 'relief-seeking measures that kill you eventually' — that include four she described as 'Whac-a-mole addictions': work, love, sex, and shopping. Overworking is her strongest addiction, she added, 'Because the number one priority is being clicked into some seed of productivity. There's no worth in just being. And it's a higher power thing, so work addiction is also called the praise addiction.' 'If I said, 'Oh, I did heroin till four in the morning and totally blacked out,' people would be like, 'Oh shit. B–ch needs some help,'' she continued. 'But if I said, 'I've been working my f–king ass off for this deadline and I finished at 4.15 a.m.,' people would be patting my back and be, like, 'Good work, girl.' It's equally corrosive. Because any addiction, if we keep going with it, we're dead. It is great for 20 minutes, then you're dead.' Elsewhere in the interview Morissette said she identifies as highly sensitive and as an empath, traits that have complicated her rise in the music industry. 'I have an anxious, depressive tendency. Those who are sensitive are much more susceptible to their environmental information,' she said. 'If you put a highly sensitive person in an environment where they're brow-beaten or reduced, they'll basically want to kill themselves. It's the worst. If you put a highly sensitive person in an environment where they're supported, championed and listened to, they thrive.' Morisette also touched on the 1990s, when her career really took off. 'We thought that whole era was done, right? We sorted this out! Didn't we? Oh, we didn't. We dropped the ball. The collarbone thing came back in … and the hyper-sexualization thing is so boring,' she said. 'Of course, a perimenopausal woman's going to say that, right? My procreative imperative is, thank f–king God, chilling out,' Morisette continued. 'There are gorgeous things that come along with that – less people-pleasing, more directness. But I'm still in the middle of it. And that can be disconcerting. Most of my friends are in the middle of it, too, so we cut each other a lot of slack. My menopausal women friends are like, 'Honey, it gets f–king great.'' Read the interview in full on The Guardian. The post Alanis Morissette Says Work, Love, Sex and Shopping are Her 'Whac-a-Mole' Addictions: 'There's No Worth in Just Being' appeared first on TheWrap.
